BUZZ - StubHub shares rise after Citigroup upgrades rating to "Buy"
路透社2026/09/18 12:06September 18 - ** Ticketing platform StubHub (STUB.N) shares rose 4.5% in pre-market trading to $6.21
** Citigroup raised its rating on the stock from "Neutral" to "Buy"; target price cut from $9 to $7
** Citigroup said some investors are skeptical about the company’s increased EBITDA forecast, stating “given the positive impact from the World Cup in the first half of 2026,” but “based on strong APP downloads in Q3 2026, we believe the company will report better-than-expected adjusted EBITDA for Q3 2026, bringing its full-year adjusted EBITDA close to the high end of company’s guidance,” according to Citigroup
** Earlier this month, the company raised its adjusted EBITDA forecast for 2026 to $420 million, below analysts’ expectation of $457.34 million — data compiled by London Stock Exchange Group (LSEG)
** As of the previous trading day’s close, the company’s share price had fallen by 56.1% year-to-date
(To assist non-native English speakers, Reuters provides automated translations of its reports into several other languages. As automated translations may contain errors or lack the required context, Reuters does not guarantee the accuracy of these translated texts. They are provided solely for the convenience of readers. Reuters will not be liable for any damage or loss arising from the use of automated translation features.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
After Eli Lilly's nearly 300% surge in four years, Wall Street remains bullish: The "hidden pipeline" beyond GLP-1 is underestimated
Eli Lilly’s share price has surged nearly 300% since the approval of its first GLP-1 drug, with its market capitalization surpassing 1 trillion USD, yet Wall Street remains optimistic about its continued growth. Berenberg has upgraded Eli Lilly’s rating to “Buy," believing that Mounjaro and Zepbound will continue to see strong volume, and that the oral GLP-1 drug could further drive demand. Additionally, Eli Lilly continues to expand into areas such as cancer and sleep disorders, and the potential of its non-obesity-related pipelines remains underestimated by the market.
BUZZ — U.S. Stock Market News: CoreWeave, StubHub, Ultragenyx
Goldman Sachs: The industrial sector is "even more expensive" than tech stocks; global sector pricing logic is changing
The 12-month forward price-to-earnings ratio of the industrial sector has now surpassed that of the technology sector, indicating that the relative valuations among various sectors in global stock markets are undergoing a shift.
BrasilAgro updates corporate financial calendar for 2026-27